U.S. stock market mid-session update: FDA agrees to review, Cantor target price $28! Capricor rises 10.53%

U.S. Stock Market Midday Update

Capricor Therapeutics, up 10.53%, with increased trading volume. Based on recent key news:

1. On August 15, the U.S. Food and Drug Administration (FDA) agreed to review the latest data for Capricor Therapeutics' Duchenne muscular dystrophy drug Deramiocel. Cantor Fitzgerald upgraded the stock rating to "Buy," significantly raising the target price from $3.50 to $28. The company's second-quarter financial report showed a net loss of $40.7 million with no revenue, but it holds approximately $237.9 million in cash reserves, sufficient to support operations for the next twelve months. The Biologics License Application (BLA) for Deramiocel is still under review, with a PDUFA date of August 22, 2026. The company plans to submit a supplemental application focusing on upper limb skeletal muscle indications. Additionally, the company has withdrawn its lawsuit against NS Pharma and is seeking arbitration to resolve the commercialization dispute over CAP-1002.

2. On August 17, Capricor Therapeutics' stock was affected by a securities fraud class action lawsuit. The lawsuit involves investors who purchased Capricor Therapeutics securities between December 17, 2025, and July 26, 2026. Investors are advised to seek lead plaintiffs before the deadline.

3. On August 17, retail traders showed a "bullish" sentiment towards Capricor Therapeutics, with high news volume. Over the past year, SLS has outperformed IBRX and Capricor Therapeutics, rising 725%, IBRX up 179%, while Capricor Therapeutics has declined 15%. The industry overall is performing strongly, with positive FDA review progress.

Top Stocks by Industry Trading Volume

Argenx, up 16.63%. Based on recent key news:

1. On August 17, Argenx reported positive results for its drug Efgartigimod in the Phase III ALKIVIA trial, significantly improving the condition of patients with autoimmune myositis. This news drove the stock price up over 14%, reaching an all-time high. Analysts expect peak sales for the drug in the IMNM field to reach $3 billion and $1.7 billion in the DM field. Source: Benzinga

2. On August 17, Argenx announced that its drug Vyvgart achieved success in the Phase III trial in the field of autoimmune myositis, with patients showing significant clinical improvement at week 52. This result sparked investor interest, driving the stock price up. Source: Dow Jones Newswires

3. On August 17, Argenx's drug Efgartigimod showed early and sustained improvement in the Phase III trial, demonstrating significant clinical effects compared to placebo. This news increased market confidence in its drug, resulting in a stock price increase Source: Reuters The biotechnology industry has recently performed strongly, with significant capital inflows.

Amgen rose 0.14%. Based on recent news,

1. On August 17, Barclays raised Amgen's target price from $360 to $380, maintaining a neutral rating. This move indicates that analysts hold a cautiously optimistic view of Amgen's future performance, driving a slight increase in the stock price.

2. On August 17, MarketBeat reported that Amgen was not included in the list of five stocks recommended by top analysts, despite maintaining a hold rating. This may lead to a decrease in confidence among some investors regarding Amgen, but the overall impact is limited.

3. On August 15, MarketBeat reported the latest situation of hedge funds holding Amgen stock, showing that institutional investors still have interest in Amgen, supporting stock price stability. The competition in the pharmaceutical industry is intensifying, and market volatility is evident.

AbbVie rose 0.31%. Based on recent news,

1. On August 15, Glenview Capital Management increased its position in AbbVie, demonstrating confidence in the company, which drove the stock price up. According to the latest 13F filing, Glenview Capital Management holds approximately 149K shares of AbbVie stock.

2. On August 17, market rumors suggested that AbbVie has a new blockbuster business emerging, further boosting investor confidence and driving the stock price up.

3. On August 17, MarketBeat pointed out that although AbbVie currently has a moderate buy rating among analysts, top analysts believe there are five other stocks that are more worthy of purchase, which may exert some downward pressure on the stock price. The pharmaceutical industry as a whole is entering a phase of high-quality development.

Stocks ranked at the top of the industry by market capitalization

Gilead Sciences rose 0.19%, with a market capitalization reaching $171.9 billion, and trading volume increased, with no significant news recently. The trading is active, and capital flows are evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation